Clinical Trial

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 3, 2024 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study was an open-label, multicenter, randomized study. It is planned to include 136 patients with stage II-III triple negative breast cancer. Eligible subjects will be randomized to receive either the experimental arm: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin) or the control arm: adebrelimab plus nab-paclitaxel + carboplatin.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-10.
Status change: Not Yet Recruiting → Recruiting 2024-01-02
Trial Details
NCT Number NCT06165900
Lead Sponsor Shengjing Hospital
Conditions Stereotactic Radiotherapy, Immunotherapy, Breast Cancer
Enrollment 136 participants
Start Date 2023-09-26
Primary Completion 2025-12-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2024-01-03